课题基金 / 基金详情

Role of Matrix Metalloproteinase-1 in Endothelial Cell Senescence

Role of Matrix Metalloproteinase-1 in Endothelial Cell Senescence
基质金属蛋白酶-1在内皮细胞衰老中的作用
批准号:
7934615
负责人:
Catherine D Mao
金额:
$18.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-11-30

项目摘要

项目成果

Catherine D Mao的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):体外由癌基因和氧化应激诱导的细胞过早衰老重现了复制性衰老和体内细胞衰老的许多方面。随着衰老细胞在体内的肿瘤抑制作用的最新发现,细胞衰老的建立作为对应激的生存适应出现,旨在限制应激和受损细胞的增殖。然而,细胞衰老建立和维持的因素和分子机制仍然知之甚少。锂通常用于治疗双相情感障碍,以及通过抑制糖原合成酶激酶(GSK)-32激活致癌2-连环蛋白信号通路。我们以前已经表明,锂诱导原代内皮细胞的细胞周期停滞与肿瘤抑制因子p53和p21 cip级联的激活和细胞衰老表型的发展,其特征在于SA- 2-半乳糖苷酶标记。锂诱导的衰老表型还伴随着肿瘤抑制因子FOXO 1的激活,FOXO 1参与寿命和细胞衰老的控制,并通过纤溶酶原激活物抑制剂(派)-1和基质金属蛋白酶(MMP)-1的上调,这两种分泌的细胞衰老和年龄相关疾病的标志物。MMP-1除了降解胶原外,还可以通过蛋白酶激活受体(PAR)-1的切割和激活来传递信号。内皮细胞中PAR 1的激活触发促炎状态,这也是衰老状态的标志。此外,MMP 1上调锂是一个早期事件,似乎独立于炎性细胞因子,GSK 32抑制和2-连环蛋白稳定指示一种新的锂依赖性级联反应。我们建议测试的假设,一种新的锂依赖性级联诱导MMP-1的表达,这反过来又参与建立和/或维持细胞衰老通过激活PAR-1。在目的1中,我们将通过以下方式确定MMP-1在锂诱导的细胞衰老表型的建立中的作用及其作用机制:i)分别使用特异性抑制剂和小RNA干扰监测存在MMP-1和不存在MMP-1活性和表达时衰老标志物的表达,和ii)通过分析PAR-1响应锂的活化及其对MMP-1表达和活性的依赖性。在目的2中,我们将通过i)描绘MMP-1启动子中的锂响应元件,ii)鉴定由锂调节的转录因子和iii)分析使用特异性抑制剂和激活剂以及通过小RNA干扰敲低其表达所涉及的信号级联,来鉴定锂介导的MMP-1在内皮细胞中上调的机制。公共卫生相关性:癌症和动脉粥样硬化的发生随着年龄的增长而增加,并且这些与年龄相关的疾病具有共同的特征,例如在病变内或周围出现衰老细胞。虽然细胞衰老是对压力的生存反应,但这些衰老细胞释放因子,如基质金属蛋白酶-1,这反过来又会维持和传播细胞功能障碍状态。因此,了解这些因子如何产生以及它们如何作用于邻近细胞对于开发新的靶向治疗策略以预防或延迟与衰老相关的细胞功能障碍的传播至关重要。
英文摘要
DESCRIPTION (provided by applicant): Premature cell senescence induced by oncogenes and oxidative stress in vitro recapitulates many facets of replicative senescence and in vivo cellular aging. With the recent findings of a tumor suppressor role for senescent cells in vivo, the establishment of cell senescence emerges as a survival adaptation to stress aimed at limiting the proliferation of stressed and damaged cells. However, the factors and molecular mechanisms by which cell senescence is established and maintained remain poorly understood. Lithium is commonly used to treat bipolar disorder as well as to activate the oncogenic 2-catenin signaling pathway via inhibition of glycogen synthase kinase (GSK)-32. We have previously shown that lithium induces a cell cycle arrest in primary endothelial cells associated with the activation of the tumor suppressor p53 and p21cip cascade and the development of a cell senescent phenotype characterized by the SA- 2-galactosidase marker. The lithium-induced senescent phenotype was also accompanied with the activation of the tumor suppressor FOXO1, which is involved in the control of lifespan and cell senescence and by the up-regulation of plasminogen activator inhibitor (PAI)-1 and matrix metalloproteinase (MMP)-1, two secreted markers of cell senescence and age-related diseases. MMP-1, in addition to degrade collagen, can signals via cleavage and activation of the proteinase-activated-receptor (PAR)-1. Activation of PAR1 in endothelial cells triggers a pro-inflammatory state, which is also a hallmark of a senescent state. Moreover, MMP1 up-regulation by lithium is an early event that appears independent of inflammatory cytokines, GSK32 inhibition and 2-catenin stabilization indicative of a novel lithium-dependent cascade. We propose to test the hypothesis that a novel lithium-dependent cascade induces MMP-1 expression, which in turn participates in the establishment and/or maintenance of cell senescence via activation of PAR-1. In Aim 1, we will determine the role of MMP-1 in the establishment of lithium-induced cell senescent phenotype and its mechanism of action by i) monitoring the expression of senescence markers in presence of MMP-1 and in absence of MMP1 activity and expression using specific inhibitors and small RNA interference respectively, and ii) by analyzing the activation of PAR-1 in response to lithium and its dependency on MMP-1 expression and activity. In Aim 2, we will identify the mechanisms of lithium-mediated up-regulation of MMP-1 in endothelial cells by i) delineating the lithium- responsive element in MMP-1 promoter, ii) identifying the transcription factors regulated by lithium and iii) analyzing the signaling cascade involved using specific inhibitors and activators as well as by knock in down their expression by small RNA interference. PUBLIC HEALTH RELEVANCE: The occurrence of cancer and atherosclerosis increase with age and these age-related diseases share common features such as the appearance of senescent cells within or around the lesions. Though cell senescence is a survival response to stress, these senescent cells release factors, like the matrix metalloproteinase-1, that will in turn maintain and propagate cellular dysfunctional states. Thus understanding how these factors are produced and how they act on neighboring cells is crucial for developing novel and targeted therapeutic strategies to prevent or delay the propagation of cellular dysfunctions associated with aging.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.bbrc.2010.07.062
发表时间: 2010-08-20
期刊: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子: 3.1
作者: [Struewing, Ian, Boyechko, Tania, Barnett, Corey, Beildeck, Marcy, Byers, Stephen W., Mao, Catherine D.]
通讯作者: Mao, Catherine D.
WNT13 & WNT13-signaling in Endothelial Cell Survival
  • 批准号:
    6683200
  • 项目类别:
  • 资助金额:
    $25.34万
  • 财政年份:
    2001
  • 负责人:
    Catherine D Mao
  • 依托单位:
WNT13 & WNT13-signaling in Endothelial Cell Survival
  • 批准号:
    6417888
  • 项目类别:
  • 资助金额:
    $4.06万
  • 财政年份:
    2001
  • 负责人:
    Catherine D Mao
  • 依托单位:
WNT13 & WNT13-signaling in Endothelial Cell Survival
  • 批准号:
    6594963
  • 项目类别:
  • 资助金额:
    $25.54万
  • 财政年份:
    2001
  • 负责人:
    Catherine D Mao
  • 依托单位:
WNT13 & WNT13-signaling in Endothelial Cell Survival
  • 批准号:
    6677867
  • 项目类别:
  • 资助金额:
    $25.34万
  • 财政年份:
    2001
  • 负责人:
    Catherine D Mao
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: